In today's AFR page 24
"It's time to get biotechnical"
a snip
"Chief executive Thomas Liquard says if the trial is a success, the drug HA-Irinotecan could hit sales of at least $400 million and up to $1 billion based on a similar product that is used to treat breast cancer. "We're probably undervalued by half right now," he argues pointing to the US cancer drug developers."
I have a hard copy, so I am not sure if this link is the correct one, although most likely, as most of the same companies discussed.
http://www.afr.com/p/personal_finance/smart_money/how_to_pick_the_next_hot_biotechnology_sm5ohPvRfgmZNwzW1HNYIM
- Forums
- ASX - By Stock
- TSN
- probably undervalued by half....
probably undervalued by half....
-
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable